CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 2.33: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.27%
Annual Rate
CNY 0.25Paid unknown
Payout Ratio
14.0%Sustainable
Payback Period
82.2 yr
Last Ex-Dividend
Jun 15, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.16BCNY618.17M · vs all stocks (USD)
Trailing P/E
37.86xvs Biotechnology peers
Revenue (TTM)
1.46BCNY217.26M · vs all stocks (USD)
Profit Margin
7.67%vs Biotechnology peers
Beta
0.3480xvs all stocks
52-Week Change
-53.82%vs all stocks
Forward Annual Dividend Yield
1.27%vs all stocks
Market Capitalization
4.16BCNY618.17M · vs all stocks (USD)
Enterprise Value
5.05BCNY751.41M · vs all stocks (USD)
Trailing P/E
37.86xvs Biotechnology peers
Forward P/E
24.50xvs Biotechnology peers
Price to Sales (TTM)
2.98xvs Biotechnology peers
Price to Book (MRQ)
2.47xvs Biotechnology peers
Enterprise to Revenue
3.46xvs Biotechnology peers
Enterprise to EBITDA
35.01xvs Biotechnology peers
Gross Margin
58.65%vs Biotechnology peers
Profit Margin
7.67%vs Biotechnology peers
Operating Margin
-1.35%vs Biotechnology peers
Return on Assets (TTM)
0.87%vs Biotechnology peers
Return on Equity (TTM)
6.44%vs Biotechnology peers
Revenue (TTM)
1.46BCNY217.26M · vs all stocks (USD)
Revenue per Share (TTM)
7.39CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-20.70%vs Biotechnology peers
Gross Profit (TTM)
894.26MCNY132.99M · vs all stocks (USD)
EBITDA (TTM)
239.44MCNY35.61M · vs all stocks (USD)
Net Income (TTM)
112.05MCNY16.66M · vs all stocks (USD)
Operating Cash Flow (TTM)
67.50MCNY10.04M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-87.92MCNY-13.07M · vs all stocks (USD)
Forward Annual Dividend Rate
0.2500CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
1.27%vs all stocks
Trailing Annual Dividend Rate
0.2500CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.27%vs all stocks
Payout Ratio
14.04%vs Biotechnology peers
Minority Interest (Equity)
1.51MCNYFY2025 · Dec 31, 2025Revenue
1.53BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
561.97MCNYFY2025 · Dec 31, 2025Gross Profit
972.05MCNYFY2025 · Dec 31, 2025Operating Income
97.61MCNY14.52M · vs all stocks (USD)
Pre-tax Income
165.70MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.96MCNYFY2025 · Dec 31, 2025Net Income
152.74MCNYFY2025 · Dec 31, 2025EBIT
207.61MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
239.44MCNYFY2025 · Dec 31, 2025Research & Development
199.55MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
508.11MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
41.91MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
196.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
196.92MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
152.74MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.82MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-13.74MCNYFY2025 · Dec 31, 2025Free Cash Flow
-96.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
648.32MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
152.74MCNYFY2025 · Dec 31, 2025Other Non-cash Items
48.91MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-224.91MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
9.52MCNYFY2025 · Dec 31, 2025Capital Expenditures
-82.46MCNYFY2025 · Dec 31, 2025Net Acquisitions
12.43MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.77BCNYFY2025 · Dec 31, 2025Sale of Investments
1.78BCNYFY2025 · Dec 31, 2025Other Investing Activity
-2.11MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-63.76MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
916.43MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-732.42MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-57.38MCNYFY2025 · Dec 31, 2025Other Financing Charges
-53.31MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
73.31MCNYFY2025 · Dec 31, 2025Shares Outstanding
201.26MSharesUpdated Aug 21, 2026Float Shares
95.59MSharesUpdated Aug 21, 2026% Held by Insiders
52.69%vs all stocks
% Held by Institutions
5.35%vs all stocks
Total Cash (MRQ)
628.04MCNY93.40M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.17CNYUpdated Aug 21, 2026Total Debt (MRQ)
1.41BCNY209.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.8158xvs Biotechnology peers
Current Ratio (MRQ)
1.50xvs Biotechnology peers
Book Value per Share (MRQ)
8.73CNYUpdated Aug 21, 2026Total Assets
3.53BCNY525.47M · vs all stocks (USD)
Total Current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Liabilities
1.78BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
759.79MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.02BCNYFY2025 · Dec 31, 2025Cash
642.76MCNYFY2025 · Dec 31, 2025Cash Equivalents
7.67MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
650.43MCNYFY2025 · Dec 31, 2025Accounts Receivable
579.78MCNYFY2025 · Dec 31, 2025Inventory
139.22MCNYFY2025 · Dec 31, 2025Accounts Payable
229.18MCNYFY2025 · Dec 31, 2025Short-term Debt
667.24MCNYFY2025 · Dec 31, 2025Other Current Liabilities
32.61MCNYFY2025 · Dec 31, 2025Long-term Debt
729.52MCNYFY2025 · Dec 31, 2025Common Stock (Book)
201.26MCNYFY2025 · Dec 31, 2025Retained Earnings
270.70MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.75BCNY260.62M · vs all stocks (USD)
Treasury Stock
80.36MCNYFY2025 · Dec 31, 202552-Week Low
17.00CNYUpdated Aug 21, 202652-Week High
46.41CNYUpdated Aug 21, 202652-Week Change
-53.82%vs all stocks
Beta
0.3480xvs all stocks
50-Day MA
19.58CNYUpdated Aug 21, 2026200-Day MA
27.41CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.10MSharesUpdated Aug 21, 2026Avg 30-Day Volume
5.67MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.5700CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: 0.08
Financial Health
Altman Z-Score 2.33: grey zoneSignificant
Altman Z-Score: 2.33
Low earnings qualitySignificant
Earnings Quality Score: -0.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
AvenuesAI Limited
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Sichuan Shengda Forestry Industry Co. Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Shandong Himile Mechanical Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated